Greenwich LifeSciences, Inc.

NasdaqCM GLSI

Greenwich LifeSciences, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Greenwich LifeSciences, Inc. Revenue Per Share is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Greenwich LifeSciences, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Greenwich LifeSciences, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Greenwich LifeSciences, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a 0.00% change year over year.
Greenwich LifeSciences, Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 0.00.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

NasdaqCM: GLSI

Greenwich LifeSciences, Inc.

CEO	Mr. Snehal S. Patel
IPO Date	Sept. 25, 2020
Location	United States
Headquarters	Building 14
Employees	3
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Key trends

Past 5 years